Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned Sarah A. JonesEric F. Morand Leading Article Open access 28 May 2024 Pages: 625 - 635
Therapeutic Potential of Lipoprotein(a) Inhibitors Stephen J. Nicholls Leading Article Open access 08 June 2024 Pages: 637 - 643
Postpartum Depression: A Clinical Review of Impact and Current Treatment Solutions Cindy-Lee DennisDaisy R. SinglaSimone N. Vigod Review Article 30 May 2024 Pages: 645 - 659
Anti-IL-5 Pathway Agents in Eosinophilic-Associated Disorders Across the Lifespan Carlo LombardiPasquale ComberiatiAlvise Berti Review Article Open access 08 June 2024 Pages: 661 - 684
Sex-Based Outcomes of Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention: A Pairwise and Network Meta-Analysis Thomas A. AgbaedengJean Jacques NoubiapAzmeraw T. Amare Systematic Review 29 May 2024 Pages: 685 - 701
Understanding Differences in Sex-Based Outcomes with Dual Antiplatelet Therapy After Percutaneous Coronary Intervention Ibrahim AkinNazha HamdaniIbrahim El-Battrawy Commentary 29 May 2024 Pages: 703 - 705
Ensitrelvir Fumaric Acid: First Approval Yahiya Y. Syed ADISINSIGHT REPORT 25 May 2024 Pages: 721 - 728
Cefepime/Enmetazobactam: First Approval Susan J. Keam ADISINSIGHT REPORT 18 May 2024 Pages: 737 - 744
Correction: Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo Connie Kang Correction Open access 29 May 2024 Pages: 745 - 745
